Home » Newsletters » BioWorld Science

BioWorld Science

Jan. 30, 2009

View Archived Issues

Histamine H3 receptor modulators for treating obesity developed at Roche

Argenta and AstraZeneca jointly impart novel muscarinic M3 receptor antagonists

New cathepsin K inhibitors developed at AstraZeneca

Roche divulges antipsychotic tachykinin NK3 receptor antagonists

Novel protein kinase inhibitors manufactured at Abbott

Helsinn acquires Sapphire Therapeutics

Synvista Therapeutics terminates alagebrium and SYI-2074 trials

Gilead Sciences: Q4 overview

Connexin43 mimetic peptide shows promise in spinal cord contusion injury model

Agents interfering with Wnt pathway responses identified

Cannasat to commence phase Ib CAT-310 study for neuropathic pain

Soliris receives marketing approval in Canada for patients with PNH

International Stem Cell Corp. begins preclinical human corneal epithelial cell trial

Patient recruitment completed in Biofrontera's phase III BF-200 ALA study

FDA approves gastric ulcer incidence as primary endpoint in Pozen's clinical programs

FDA accepts as complete Eurand's response to June 2008 approvable letter for EUR-1008

Biothera expands second arm of clinical trial of Imprime PGG and Erbitux in mCRC

Roche to initiate cash tender offer for all outstanding publicly held shares of Genentech

Acrux ceases development of Fentanyl MDTS for chronic pain

Alexza to focus resources on Staccato loxapine for acute agitation

Isotechnika provides update on its lead product voclosporin

Lipoxen reports interim results for long-acting erythropoietin candidate

Merrion collaborates with Novo Nordisk on GLP-1 receptor agonist development

TheraGenetics acquired by Avacta Group

Zavesca receives E.U. approval for treatment in Niemann-Pick type C disease